# AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

> **NCT01233687** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ahmad Tarhini** · enrollment: 49 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** AMG 102 and erlotinib

## Key facts

- **NCT ID:** NCT01233687
- **Lead sponsor:** Ahmad Tarhini
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2017-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01233687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01233687, "AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01233687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*